Trially is a technology company.
Trially has raised $5.0M across 1 funding round.
Trially has raised $5.0M in total across 1 funding round.
Trially is an AI-powered platform that automates patient identification, matching, and enrollment for clinical trials by integrating with electronic health records (EHRs), clinical trial management systems (CTMS), and customer relationship management (CRM) tools.[1][2][6] It serves research sites, hospitals, sponsors, contract research organizations (CROs), and providers, solving the core problem of trial delays—86% of trials face recruitment bottlenecks, costing sponsors over $600K daily and sites 250+ hours monthly on manual chart reviews—by delivering ~95% screening accuracy, 2-6x more enrollments in complex studies, and real-time protocol analysis.[1][2][4][5][6] Founded in 2023 in Kansas City, Missouri, Trially recently raised $4.7M in seed funding led by Flyover Capital and launched its agentic AI solution, Margo, to convert matches into enrollments via HIPAA-compliant large language models (LLMs).[3][4]
Trially was founded in 2023 by CEO Kyle McAllister, CTO Ramon Prieto, and Trevor Welch in Kansas City, Missouri.[1][2][3] McAllister, an industry veteran and entrepreneur with successful exits, drew from personal experience with customer pain points in clinical trials, while Prieto (ex-Zapier, where he re-architected its $5B data infrastructure) and Welch brought machine learning and AI expertise from Zapier.[3][5] The idea emerged to address inefficiencies in patient recruitment, such as manual EHR reviews and high screen failures; early traction came from integrations with sites like ClinTrial Research, boosting KPIs across therapy areas like CNS and oncology.[1][3] Pivotal moments include a $4.7M seed round in 2025 (with investors like Atria and Gaingels) and hiring serial entrepreneur Christian Smith as CRO.[3][4]
Trially rides the AI-in-healthcare wave, specifically agentic AI and LLMs for unstructured clinical data, amid a $50B+ clinical trials market plagued by recruitment delays that inflate costs and slow therapies.[4][5] Timing aligns with post-pandemic trial acceleration demands, EHR digitization, and regulatory pushes for diversity/efficiency; market forces like pharma's daily losses and sites' manual burdens favor scalable AI over ads.[1][3][5] It influences the ecosystem by bridging sites, sponsors, and health systems—potentially expanding to physician-led trial discovery—positioning Trially as a leader in unlocking "untapped patient data" for faster drug development.[3][5]
Trially's seed funding and Margo launch signal rapid scaling across CROs, pharma, and physician networks, with plans to mesh site and health system sides for mega-opportunities in trial discovery.[3][4] Trends like multimodal AI, real-world evidence integration, and decentralized trials will amplify its edge, potentially evolving into a full-stack enrollment platform amid rising AI adoption in life sciences. As the bridge from protocol to patient, Trially could redefine trial speed, delivering therapies faster while commanding premium site/sponsor adoption.[1][3][4]
Trially has raised $5.0M in total across 1 funding round.
Trially's investors include Flyover Capital, High Alpha.
Trially has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $5.0M Seed | Flyover Capital, High Alpha |